Tonghua Dongbao to invest up to 162 million yuan in Amoytop Biotech convertible bonds

财中社··Read original
2▲1 ▼0Impact / 5
Summary · why it matters

Tonghua Dongbao plans to exercise its preemptive subscription rights to participate in the purchase of convertible corporate bonds issued by Xiamen Amoytop Biotech to non-specific investors, with an investment amount not exceeding 162 million yuan. The company holds 42.01 million shares of Amoytop Biotech, representing a 10.29 percent stake. The investment principal for this subscription accounts for 2.28 percent of the company's audited net assets for 2025 and 2.24 percent of its unaudited net assets for the first quarter of 2026. The total proceeds from Amoytop Biotech's convertible bond issuance will not exceed 1.533 billion yuan. Tonghua Dongbao classifies this investment as a financial asset measured at fair value through profit or loss, and changes in fair value will affect the company's net profit. In the first quarter of 2026, Tonghua Dongbao achieved revenue of 748 million yuan and net profit attributable to the parent company of 127 million yuan.

Impact on assets 2

Others▲ · 2 stocks
Xiamen Amoytop Biotech Co Ltd
688278
▲ PositiveCapitalrelevance

Amoytop Biotech receives up to 1.533 billion yuan from convertible bond issuance, providing capital for its operations or growth.

Tonghua Dongbao Pharmaceutical Co Ltd
600867
± MixedCapitalrelevance

Tonghua Dongbao invests up to 162 million yuan in Amoytop Biotech convertible bonds, classified as financial asset at fair value through profit or loss; impact depends on future fair value changes.

© 2026 MarketIVNews